JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB306823

Human PML knockout U-87 MG cell line

Be the first to review this product! Submit a review

|

(0 Publication)

PML KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Next Generation Sequencing - Human PML knockout U-87 MG cell line (AB306823)
  • NGS

Supplier Data

Next Generation Sequencing - Human PML knockout U-87 MG cell line (AB306823)

109 bp deletion after Ala135 (allele 1) and 107 bp deletion after Asp136 (allele 2) of the WT protein

Key facts

Cell type

U-87 MG

Species or organism

Human

Tissue

Brain

Form

Liquid

form

Knockout validation

Next Generation Sequencing

Disease

Glioblastoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "NGS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab306823-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab279979 Human wild-type U-87 MG cell line", "number":"AB306823-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab306823 Human PML knockout U-87 MG cell line", "number":"AB306823-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab306823-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab306823 Human PML knockout U-87 MG cell line", "number":"AB306823-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PML
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

EMEM + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The PML protein also known as promyelocytic leukemia protein has a mass of about 97 kilodaltons. PML is typically expressed in the nucleus in distinct structures called nuclear bodies. These nuclear bodies often referred to as PML-nuclear bodies or PML-NBs serve several functions within the cell. The PML protein is commonly identified in tissues such as the bone marrow and blood cells where it plays a significant role in various cellular processes. Numerous antibodies including anti-PML are used to study the distribution and function of PML protein in different cellular contexts.
Biological function summary

The PML protein interacts with various molecular partners and forms a part of multiprotein complexes within the PML-nuclear bodies. Its functions include the regulation of transcription induction of apoptosis DNA damage response and control of cell proliferation. PML can recruit other proteins such as p53 a tumor suppressor protein to influence these cellular activities. PML's ability to act as a scaffold within these complexes makes it essential for maintaining cellular homeostasis and response to stress. Various techniques such as PML protein ELISA are used to analyze PML-related biological activities.

Pathways

The PML protein plays a significant role in critical cellular pathways such as apoptosis and the interferon response pathway. PML's interaction with the p53 protein links it to the apoptosis pathway where it acts as an inducer of cell death in response to cellular stress and damage. In the interferon response pathway PML contributes to antiviral defense mechanisms. The involvement of PML in these pathways emphasizes its importance in cellular defense and programmed cell death. Related proteins like STATs (signal transducers and activators of transcription) are known to interact with PML in these pathways.

Abnormalities in PML protein expression and function are linked to specific diseases including acute promyelocytic leukemia (APL) and certain types of cancer. Acute promyelocytic leukemia is characterized by a translocation involving the PML gene resulting in the PML-RARα fusion protein which interferes with normal cell differentiation. PML also relates to neurodegenerative disorders where changes in PML expression impact cellular stress responses. In the context of these diseases the PML protein's interaction with oncogenic proteins like RARα in leukemia highlights its role in disease development and potential as a therapeutic target.

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com